(MedPage Today) — The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including osimertinib (Tagrisso, as…
Source link : https://www.medpagetoday.com/spotlight/asco-nsclc/116466
Author :
Publish date : 2025-07-11 16:04:00
Copyright for syndicated content belongs to the linked Source.
